The Biotechnology Innovation Organization (BIO) recognizes the need for our member companies to share mission-critical resources with other BIO members during the Coronavirus pandemic. To that end, we will be relaxing our policies on posting company sales or marketing information on BIO.org, to the extent such information is relevant to helping BIO members respond to the pandemic. Accepted information on products and services related to the COVID-19 response will be posted as part of BIO’s Coronavirus Business Response Center. This information will be posted through April 30, 2020; this date will be re-evaluated as the date approaches.
The Biotechnology Innovation Organization (BIO) is providing this information and links below only as a source of potentially relevant information, and inclusion of such information on this website is not, and should not be construed as, a direct or indirect endorsement of the products or services by BIO.
BIO pools the purchasing power of thousands of life sciences companies to negotiate bulk pricing and favorable terms at certain partner organizations. These companies provide critical services to BIO member companies every day; therefore, their products, services, or offers will be posted as requested. The BIO Business Solutions program is only open to BIO members and members of BIO’s state-based partners. You can learn more at bio.org/save.
How to create a small business continuity plan for your startup. Is your company prepared for a crisis? This article provides a tested, up-to-date plan that’s ready to execute for your startup.
BIO’s membership includes many important industry service providers. We consider these companies members of the greater life sciences community, and therefore their products, services or other offers of assistance will be posted as requested. To post helpful information for your fellow BIO members please email email@example.com.
The Akin Gump COVID-19 Resource Center will deliver timely insights and analysis on the latest legal, regulatory and technical developments tailored to industry-specific interests and issues.
Sidley has organized a multidisciplinary task force to address the wide range of regulatory, transactional, and litigation issues companies face in responding to the coronavirus outbreak.
BIO will not accept unsolicited, direct posting requests from non-BIO member companies. If you’re a non-BIO member and would like to post a product, service or offer, it must come through a recommending BIO member company. Without a recommendation, we will not accept or post this information. Please contact a BIO member to recommend your company.
The Benchling platform can be rapidly configured to support COVID-19 diagnostics workflows, including but not limited to qPCR workflows.
Supported by Wake Forest Baptist Medical Center, Javara Research, and Oracle, the COVID-19 Community Research Project study tracks COVID-19 outcomes through the Patient Monitoring System and Therapeutic Monitoring System to provide policy-makers and healthcare workers with crucial information about the coronavirus.